Harpoon Therapeutics, Inc. (HARP)

NASDAQ: HARP · IEX Real-Time Price · USD
2.36
0.36 (18.00%)
At close: May 16, 2022 4:00 PM
2.38
0.02 (0.85%)
After-hours:May 16, 2022 7:51 PM EDT
Market Cap78.07M
Revenue (ttm)20.55M
Net Income (ttm)-75.32M
Shares Out33.08M
EPS (ttm)-3.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,754,036
Open2.10
Previous Close2.00
Day's Range2.10 - 2.79
52-Week Range1.73 - 22.74
Beta1.10
AnalystsBuy
Price Target14.79 (+526.7%)
Earnings DateMay 12, 2022

About HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II cl...

IndustryBiotechnology
IPO DateFeb 8, 2019
CEOGerald McMahon
Employees99
Stock ExchangeNASDAQ
Ticker SymbolHARP
Full Company Profile

Financial Performance

In 2021, HARP's revenue was $23.65 million, an increase of 35.60% compared to the previous year's $17.44 million. Losses were -$116.72 million, 133.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for HARP stock is "Buy." The 12-month stock price forecast is 14.79, which is an increase of 526.69% from the latest price.

Price Target
$14.79
(526.69% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Best Penny Stocks to Buy This Week? 3 to Watch Right Now

Check these penny stocks out for your watchlist right now The post Best Penny Stocks to Buy This Week? 3 to Watch Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...

Other symbols:AGRIDTST
8 hours ago - PennyStocks

Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Misses Revenue Estimates

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of -29.17% and 47.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial...

4 days ago - GlobeNewsWire

Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small...

HPN328, Harpoon's DLL3-targeting T cell engager, to be evaluated in combination with anti-PD-L1 antibody in patients with small cell lung cancer HPN328, Harpoon's DLL3-targeting T cell engager, to be ev...

2 weeks ago - GlobeNewsWire

Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by ...

TriTAC-XR demonstrates extended release mechanism that confirms accumulation of active drug which improves therapeutic index TriTAC-XR demonstrates extended release mechanism that confirms accumulation ...

1 month ago - GlobeNewsWire

Harpoon Therapeutics Announces Leadership Change

SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that N...

1 month ago - GlobeNewsWire

Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference

SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that m...

1 month ago - GlobeNewsWire

Harpoon Therapeutics Discontinues Its Once Lead Prostate Cancer Candidate

Harpoon Therapeutics Inc (NASDAQ: HARP), in its Q4 FY21 earnings results, has given up on its onetime lead prospect HPN424.  "We are focusing our resources on portfolio programs that show promising acti...

2 months ago - Benzinga

Harpoon Therapeutics, Inc. (HARP) Reports Q4 Loss, Lags Revenue Estimates

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of -43.48% and 38.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the ...

2 months ago - Zacks Investment Research

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financi...

2 months ago - GlobeNewsWire

Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that t...

2 months ago - GlobeNewsWire

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that t...

2 months ago - GlobeNewsWire

Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that ma...

3 months ago - GlobeNewsWire

Wall Street Analysts See a 274% Upside in Harpoon Therapeutics, Inc. (HARP): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 274.4% in Harpoon Therapeutics, Inc. (HARP). While the effectiveness of this highly sought-after metric is questi...

4 months ago - Zacks Investment Research

Harpoon Therapeutics Provides Pipeline Development Milestones for 2022

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a pipeli...

4 months ago - GlobeNewsWire

Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a pipeli...

5 months ago - GlobeNewsWire

Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet

Harpoon Therapeutics Inc (NASDAQ: HARP) presented a poster with interim data from the ongoing dose-escalation portion of the Phase 1/2 trial for HPN217 in patients with relapsed/refractory multiple myel...

5 months ago - Benzinga

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for ...

Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma

5 months ago - GlobeNewsWire

Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it...

5 months ago - GlobeNewsWire

Harpoon Therapeutics, Inc. (HARP) Reports Q3 Loss, Lags Revenue Estimates

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 1.92% and -29.75%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the ...

6 months ago - Zacks Investment Research

Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today report...

6 months ago - GlobeNewsWire

Harpoon Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...

6 months ago - GlobeNewsWire

Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...

6 months ago - GlobeNewsWire

Harpoon Therapeutics, Inc. (HARP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Harpoon Therapeutics, Inc. (HARP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Harpoon Therapeutics Announces Change to Management Team and Board of Directors

Julie Eastland Appointed President and Chief Executive Officer

6 months ago - GlobeNewsWire